Cargando…
Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice
SIMPLE SUMMARY: A number of agents, including immune checkpoint inhibitors, have become available for the treatment of hepatocellular carcinoma, but the objective response rate of these drugs is currently only 30% to 40%. Therefore, the identification of new predictive biomarkers and an increased kn...
Autores principales: | Motomura, Kenta, Kuwano, Akifumi, Tanaka, Kosuke, Koga, Yuta, Masumoto, Akihide, Yada, Masayoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486942/ https://www.ncbi.nlm.nih.gov/pubmed/37686621 http://dx.doi.org/10.3390/cancers15174345 |
Ejemplares similares
-
FIB‑4 index and serum α‑fetoprotein are useful predictors of hepatocellular carcinoma occurrence in hepatitis B patients with nucleos(t)ide analogs therapy
por: Kuwano, Akifumi, et al.
Publicado: (2023) -
Tumor‑infiltrating CD8(+) T cells as a biomarker for chemotherapy efficacy in unresectable hepatocellular carcinoma
por: Kuwano, Akifumi, et al.
Publicado: (2023) -
Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of Gd-EOB-DTPA-MRI
por: Kuwano, Akifumi, et al.
Publicado: (2022) -
Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/β-catenin signal activation
por: Kuwano, Akifumi, et al.
Publicado: (2022) -
Risk factors for loss to follow‐up after the start of direct‐acting antiviral treatment for hepatitis C virus infection
por: Kuwano, Akifumi, et al.
Publicado: (2022)